Indobufen

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Summary

Indobufen is a reversible platelet aggregation inhibitor used to prevent coronary and peripheral artery occlusion.

Generic Name
Indobufen
DrugBank Accession Number
DB12545
Background

Indobufen has been used in trials studying the supportive care and prevention of Atrial Fibrillation.

Type
Small Molecule
Groups
Investigational
Structure
Thumb
Weight
Average: 295.338
Monoisotopic: 295.120843411
Chemical Formula
C18H17NO3
Synonyms
  • Indobufen

Pharmacology

Indication

Not Available

Pharmacology
Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Associated Conditions
Contraindications & Blackbox Warnings
Contraindications
Avoid life-threatening adverse drug events
Improve clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events & improve clinical decision support.
Learn more
Pharmacodynamics

Not Available

Mechanism of action
Not Available
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Adverseeffects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.
Learn more
Improve decision support & research outcomes with our structured adverse effects data.
Learn more
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
AbacavirIndobufen may decrease the excretion rate of Abacavir which could result in a higher serum level.
AbciximabThe risk or severity of bleeding and hemorrhage can be increased when Indobufen is combined with Abciximab.
AcebutololIndobufen may decrease the antihypertensive activities of Acebutolol.
AceclofenacThe risk or severity of adverse effects can be increased when Aceclofenac is combined with Indobufen.
AcemetacinThe risk or severity of adverse effects can be increased when Indobufen is combined with Acemetacin.
AcenocoumarolThe risk or severity of bleeding and hemorrhage can be increased when Indobufen is combined with Acenocoumarol.
AcetaminophenThe risk or severity of adverse effects can be increased when Acetaminophen is combined with Indobufen.
AcetohexamideThe protein binding of Acetohexamide can be decreased when combined with Indobufen.
Acetylsalicylic acidAcetylsalicylic acid may increase the antiplatelet activities of Indobufen.
AclidiniumIndobufen may decrease the excretion rate of Aclidinium which could result in a higher serum level.
Interactions
Identify potential medication risks
Easily compare up to 40 drugs with our drug interaction checker.
Get severity rating, description, and management advice.
Learn more
Food Interactions
Not Available

Products

Products2
Drug product information from 10+ global regions
Our datasets provide approved product information including:
dosage, form, labeller, route of administration, and marketing period.
Access now
Access drug product information from over 10 global regions.
Access now

Categories

ATC Codes
B01AC10 — Indobufen
Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
This compound belongs to the class of organic compounds known as isoindolones. These are aromatic polycyclic compounds that an isoindole bearing a ketone.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Isoindoles and derivatives
Sub Class
Isoindolines
Direct Parent
Isoindolones
Alternative Parents
Phenylpropanes / Isoindoles / Tertiary carboxylic acid amides / Lactams / Monocarboxylic acids and derivatives / Carboxylic acids / Azacyclic compounds / Organopnictogen compounds / Organonitrogen compounds / Organic oxides
show 2 more
Substituents
Aromatic heteropolycyclic compound / Azacycle / Benzenoid / Carbonyl group / Carboxamide group / Carboxylic acid / Carboxylic acid derivative / Hydrocarbon derivative / Isoindole / Isoindolone
show 11 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
Not Available
Affected organisms
Not Available

Chemical Identifiers

UNII
6T9949G4LZ
CAS number
63610-08-2
InChI Key
AYDXAULLCROVIT-UHFFFAOYSA-N
InChI
InChI=1S/C18H17NO3/c1-2-15(18(21)22)12-7-9-14(10-8-12)19-11-13-5-3-4-6-16(13)17(19)20/h3-10,15H,2,11H2,1H3,(H,21,22)
IUPAC Name
2-[4-(1-oxo-2,3-dihydro-1H-isoindol-2-yl)phenyl]butanoic acid
SMILES
CCC(C(O)=O)C1=CC=C(C=C1)N1CC2=CC=CC=C2C1=O

References

General References
  1. FDA Thailand Product Information: Ibustrin (indobufen) oral tablets [Link]
  2. AIFA Product Information: Ibustrin (indobufen) oral tablets [Link]
PubChem Compound
107641
PubChem Substance
347828770
ChemSpider
96823
RxNav
27518
ChEBI
135239
ChEMBL
CHEMBL1765292
Wikipedia
Indobufen

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
4Not Yet RecruitingTreatmentAspirin / Indobufen / Stroke, Ischemic1
4Not Yet RecruitingTreatmentCoronary Artery Disease (CAD) / Gastro-esophageal Reflux Disease (GERD)1
4Unknown StatusTreatmentCoronary Artery Atherosclerosis1
3CompletedPreventionAtrial Fibrillation1
1Unknown StatusSupportive CareHealthy Subjects (HS)1
Not AvailableNot Yet RecruitingOtherStable Coronary Heart Disease (CHD)1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
FormRouteStrength
Tablet
Tablet200 MG
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0781 mg/mLALOGPS
logP3.04ALOGPS
logP3.31ChemAxon
logS-3.6ALOGPS
pKa (Strongest Acidic)3.83ChemAxon
pKa (Strongest Basic)-3.5ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area57.61 Å2ChemAxon
Rotatable Bond Count4ChemAxon
Refractivity83.75 m3·mol-1ChemAxon
Polarizability32.14 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Drug created on October 20, 2016 22:47 / Updated on June 05, 2021 09:12